Wang, L., Shen, J., Huang, Y., Bao, J., Shen, L., Xu, P., Cheng, S., Zhu, H., Zhao, W. (2025). Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL). Blood. https://doi.org/10.1182/blood-2025-3599